This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study compares the safety and effectiveness of two medications in children with severe osteogenesis imperfecta. Children between 1 and 17 years of age who have types III and IV osteogenesis, or who have type I osteogenesis with a history of 3 or more minimal trauma fractures in the past two years or a history of limb deformity requiring surgery are eligible. One of the medications, pamidronate, has already been shown to reduce fractures in osteogenesis imperfecta. Aledronate is a new drug of the same type as pamidronate, but it is more powerful and may be a good alternative if it is effective and safe. This study is the first time zoledronate is being used in children with osteogenesis imperfecta. This study lasts for 13 months and includes 10-15 visits. Children are treated with one of the study drugs at either 2 month or 3 month intervals during that year. Physical exams, blood and urine studies, x-rays and bone density measurements are made throughout the study. In addition to the study medication, children take multivitamins and calcium supplements. This is an international, multi-center study, and 136 children will be treated, study-wide. Half of the children will receive treatment with pamidronate and half will receive treatment with zoledronate. Some children who receive zoledronate will have additional lab work to study the pharmacokinetics (processing by the body) of this drug in children.
Showing the most recent 10 out of 502 publications
